We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

18 hedge funds and large institutions have $1.24M invested in Titan Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more capital invested

Capital invested by funds: $430K → $1.24M (+$813K)

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

0.33% more ownership

Funds ownership: 0.21% → 0.54% (+0.33%)

0% more funds holding

Funds holding: 18 → 18 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
18
Holders Change
–
Holders Change %
0%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
3
Closed
3
Calls
$13K
Puts
–
Net Calls
+$13K
Net Calls Change
-$70K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$897K
2
Barclays
Barclays
United Kingdom
+$52K
3
Renaissance Technologies
Renaissance Technologies
New York
+$17.7K
4
Group One Trading
Group One Trading
Illinois
+$14.7K
5
TRCT
Tower Research Capital (TRC)
New York
+$10.3K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$40.4K
2
VF
Virtu Financial
New York
-$16K
3
WPA
Winning Points Advisors
Florida
-$15K
4
Millennium Management
Millennium Management
New York
-$10.3K
5
Simplex Trading
Simplex Trading
Illinois
-$3.57K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$826K +$897K +43,176 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$197K – – –
Group One Trading
3
Group One Trading
Illinois
$56K +$14.7K +707 +32%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$50K – – –
Barclays
5
Barclays
United Kingdom
$48K +$52K +2,503 New
Renaissance Technologies
6
Renaissance Technologies
New York
$35K +$17.7K +850 +87%
Millennium Management
7
Millennium Management
New York
$10K -$10.3K -497 -49%
TRCT
8
Tower Research Capital (TRC)
New York
$10K +$10.3K +497 +9,940%
UBS Group
9
UBS Group
Switzerland
$7K +$3.45K +166 +87%
IA
10
IFP Advisors
Florida
$3K +$873 +42 New
LFA
11
Level Financial Advisors
New York
$1K – – –
APA
12
American Portfolios Advisors
New York
$22 – – –
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
– -$40.4K -1,947 Closed
VF
14
Virtu Financial
New York
– -$16K -771 Closed
WPA
15
Winning Points Advisors
Florida
– -$15K -584 Closed
Simplex Trading
16
Simplex Trading
Illinois
– -$3.57K -172 -91%
Bank of America
17
Bank of America
North Carolina
– -$21 -1 -9%

TTNP Hedge Fund Activity: Q1 2022 in Review

18 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2022, worth a combined $1.24M — up 189% from $430K a quarter earlier.

Fund positioning in TTNP was balanced in Q1 2022: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 3 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $897K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $40.4K sold.

  • 18 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $1.24M of Titan Pharmaceuticals stock for Q1 2022, up 189% quarter-over-quarter.
  • 3 funds opened new Titan Pharmaceuticals positions in Q1 2022 and 3 closed out, a net change of 0 holders.
  • The largest Titan Pharmaceuticals buyer in Q1 2022 was Armistice Capital, an estimated $897K added.
  • The largest Titan Pharmaceuticals seller in Q1 2022 was Susquehanna International Group, an estimated $40.4K sold.

Based on aggregated 13F filings for Q1 2022.